ReviewDer Pathologe2018
[WHO classification of myeloid neoplasms].
Review in Der Pathologe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2014, two advisory committees (one each for myeloid and lymphoid neoplasms) of about 100 pathologists, hematologists, oncologists, and geneticists met in Chicago to revise the WHO diagnostic criteria. The goal was to define disease entities that should be modified, removed, or added based on new insights. In particular, to improve a biologically meaningful classification, a number of new molecular genetic markers were included, which had proved to be of diagnostic and/or prognostic relevance. The resulting differentiated diagnostic procedure is a challenge for the hematopathologist. Not only is it necessary to pool the information from a multimodal diagnostic process and to compare the results of morphology, immunophenotyping, and clinical information. It is also essential to integrate the techniques of fluorescence in situ hybridization and next generation sequencing into the diagnostic process. Hematopathological diagnostics have become more labor-intensive and cost-intensive as a result of this further differentiation.
Indexed as
Identifiers
30374757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.